Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine
- Conditions
- Hand and Foot Skin ReactionCapecitabineHand and Foot Syndrome
- Interventions
- Dietary Supplement: Extra Virgin Olive OilDietary Supplement: Olive OilDietary Supplement: Placebo
- Registration Number
- NCT06188000
- Lead Sponsor
- Universitas Sriwijaya
- Brief Summary
The study was aimed to evaluate the efficacy of extra virgin olive oil (EVOO) supplementation compared to placebo to prevent HFS by observing changes in serum COX 2, malondialdehyde (MDA), and TNF α levels in breast cancer and colorectal cancer patients undergoing capecitabine chemotherapy. Current study was designed as a single-center prospective randomized clinical trial. The patients were Stage III or Stage IV colorectal and breast cancer patients receiving capecitabine-based chemotherapy who enrolled in the trial voluntarily. All patients were divided randomly into three groups treated with EVOO, olive oil, or placebo. The incidence of hand foot syndrome was documented. The serum COX 2, malondialdehyde (MDA), and TNF α levels before and after chemotherapy was documented.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Patients pathologically and clinically diagnosed with III or IV stadium of breast cancer or colorectal cancer.
- fully recovered after curative resection within 8 weeks
- receive adjuvant capecitabine based chemotherapy
- did not meet the eligibility criteria for chemotherapy
- had previous allergy with capecitabine or olive oil
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Extra Virgin Olive Oil Extra Virgin Olive Oil The patients was given a capsule contained extra virgin olive oil 15 milliliters twice a day. Olive Oil Olive Oil The patients was given a capsule contained olive oil 15 milliliters twice a day. Placebo Placebo The patients was given an empty capsule twice a day.
- Primary Outcome Measures
Name Time Method Serum COX-2 Concentration 3 cycle of chemotherapy (63 days) Serum COX-2 Concentration
Hand Foot Syndrome 3 cycle of chemotherapy (63 days) Patients was documented for hand and foot syndrome using WHO criteria. There were 4 grade assessed by patient symptoms of tingling or burning or painful sensation, palmar or plantar erythema or desquamation, and/or ulceration.
Serum Tumor Necrosis Factor Alpha Concentration 3 cycle of chemotherapy (63 days) Serum Tumor Necrosis Factor Alpha Concentration
Serum malondialdehyde concentration 3 cycle of chemotherapy (63 days) Serum malondialdehyde ceoncentration
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rumah Sakit Mohammad Hoesin
🇮🇩Palembang, South Sumatera, Indonesia